Douglas Fearon
| Douglas Fearon | |
|---|---|
| Born |
Douglas Thomas Fearon 16 October 1942[1] |
| Alma mater |
|
| Awards | |
| Scientific career | |
| Fields | Immunology |
| Website |
www |
Douglas Thomas Fearon FRS FRCP FMedSci (born 16 October 1942)[1][2] is an American medical immunologist, who has been since 2003 Sheila Joan Smith Professor of Immunology at the University of Cambridge and a fellow of Trinity College, Cambridge.[3][4][5][6]
Awards and honours
Fearon was elected a Fellow of the Royal Society (FRS) in 1999 and is also member of the United States National Academy of Sciences.[3] His nomination for the Royal Society reads:
| “ | The research of Douglas T. Fearon has helped establish a unifying principle in immunology; namely, that the two systems of immunity, innate and acquired, are integrated. The former identifies antigens of microbial origin to bias the response of the latter to those antigens. To support this thesis, he has 1) determined how the alternative complement pathway of innate immunity attaches C3 to microbial antigens; 2) demonstrated that the attached C3 causes antigen to be orders of magnitude more potent in eliciting an acquired immune response; and 3) characterised the CR2/CD19 receptor complex of B lymphocytes that mediates the enhanced immunogenicity of C3-bearing antigens, and the counter-regulatory coreceptor, CD22, that suppresses the cellular response to antigen.[7] | ” |
References
- 1 2 3 FEARON, Prof. Douglas Thomas. ukwhoswho.com. Who's Who. 2015 (online Oxford University Press ed.). A & C Black, an imprint of Bloomsbury Publishing plc.
- ↑ "Douglas Fearon". Debretts.
- 1 2 Nuzzo, R. (2005). "Biography of Douglas T. Fearon". Proceedings of the National Academy of Sciences. 102 (21): 7415–7417. doi:10.1073/pnas.0502415102. PMC 1140442.
- ↑ Feig, C; Jones, J. O.; Kraman, M; Wells, R. J.; Deonarine, A; Chan, D. S.; Connell, C. M.; Roberts, E. W.; Zhao, Q; Caballero, O. L.; Teichmann, S. A.; Janowitz, T; Jodrell, D. I.; Tuveson, D. A.; Fearon, D. T. (2013). "Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer". Proceedings of the National Academy of Sciences. 110 (50): 20212–7. doi:10.1073/pnas.1320318110. PMC 3864274. PMID 24277834.
- ↑ Roberts, E. W.; Deonarine, A; Jones, J. O.; Denton, A. E.; Feig, C; Lyons, S. K.; Espeli, M; Kraman, M; McKenna, B; Wells, R. J.; Zhao, Q; Caballero, O. L.; Larder, R; Coll, A. P.; O'Rahilly, S; Brindle, K. M.; Teichmann, S. A.; Tuveson, D. A.; Fearon, D. T. (2013). "Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia". Journal of Experimental Medicine. 210 (6): 1137–51. doi:10.1084/jem.20122344. PMC 3674708. PMID 23712428.
- ↑ Fearon, D. T.; Locksley, R. M. (1996). "The instructive role of innate immunity in the acquired immune response". Science. 272 (5258): 50–3. doi:10.1126/science.272.5258.50. PMID 8600536.
- ↑ "EC/1999/15: Fearon, Douglas Thomas". London: The Royal Society. Archived from the original on 5 April 2015.
Authority control  |
|---|
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.